The mixed 13F cluster shows modest net buying from asset managers but lacks insider corroboration. With Q3 earnings already released and guidance reiterated, watch for any insider Form 4 filings or a material change in the ACCEL trial timeline that could shift institutional conviction.
Drug in focus
ARDX drug pipeline →tenapanor
● Neutral Named in this fund cluster- Impact
- Phase
- Approved (IBS-C and hyperphosphatemia); Phase 3 for CIC
- Time to market
- Already on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
- Next catalyst
- None dated
What to watchTenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $2.99entry
- T+1 · 11d ago −3.68%α −3.99% · $2.88
- T+5 · 5d ago +4.35%α +1.06% · $3.12
- T+8 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Institutional 13F filings for Q3 2026 show a mixed cluster in ARDX: 6 buyers added $4.4M in net new holdings (led by Citigroup and Mackenzie Financial), while 4 sellers trimmed $977K. The buying appears to align with Q3 earnings reported two days ago (revenue up 19% YoY, narrowed net loss), but the cluster is dominated by asset managers rather than activist or high-conviction funds, and the 45-day reporting lag means positions may have changed since quarter-end.
Key Financial Metrics
Institutional Positions
Net institutional flow: $3.4M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Citigroup | DOUBLED | +338.3% | $4.7M | $3.1M |
| Mackenzie Financial | ADD | +88.5% | $3.1M | $638.0K |
| Creative Planning | DOUBLED | +410.9% | $782.0K | $554.0K |
▼ Sellers (4)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Simplex Trading | TRIM | -46.7% | $772.0K | -$496.0K |
| Wealth Enhancement Advisory Services | TRIM | -73.4% | $452.0K | -$377.0K |
| Commonwealth Equity Services | TRIM | -34.3% | $181.0K | -$102.0K |
Key Facts
- 6 institutional buyers added $4.4M in net new holdings during Q3 2026
- 4 institutional sellers trimmed $977K in aggregate
- Largest buyer: Citigroup doubled its position to $4.7M (Δ+$3.1M)
- Largest seller: Simplex Trading trimmed 46.7% of its position, reducing value by $496K
- All participants are asset managers; no activist or hedge fund with a concentrated bet
- Insider trading confluence score is low (17/100) with no open-market insider buying
- Q3 2026 earnings (reported 2 days ago) showed 19% revenue growth and narrowed net loss
Financial Impact
6 buyers accumulated $4.4M in new positions while 4 sellers reduced holdings by $977K; net institutional inflow of approximately $3.4M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- No insider buying to corroborate the institutional accumulation signal
- Cluster is dominated by asset managers, not high-conviction activist or concentrated funds
- Net buying of $3.4M is small relative to $755M market cap (0.45%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ARDX-2026-Q3 |
Track record
20 reports on ARDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 5, 202612d ago Institutional Cluster Neutral 3/10 Viewing Entry $2.99 settles Feb 3
- Nov 3, 202614d ago 8-K Neutral 4/10 No price data
- Nov 3, 202614d ago Press Release Neutral 4/10 Entry $3.29 settles Feb 2
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $3.39 settles Dec 30
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $3.83 settles Nov 19
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $3.83 settles Nov 19
- Aug 21, 202612w ago 144 Neutral 2/10 Entry $3.74 to $3.18 ▼ −14.97% −10.91% vs SPY
- Aug 21, 202612w ago 144 Neutral 2/10 Entry $3.74 to $3.18 ▼ −14.97% −10.91% vs SPY
- Aug 17, 202613w ago 8-K Neutral 2/10 Entry $3.92 to $3.01 ▼ −23.21% −21.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers